key: cord-0049412-yy4u3n1n
authors: Karakonstantis, Stamatis; Kritsotakis, Evangelos I; Gikas, Achilleas
title: Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
date: 2020-09-01
journal: Infection
DOI: 10.1007/s15010-020-01520-6
sha: 04c55f6f513ace6e98f97428c31948ca5f403160
doc_id: 49412
cord_uid: yy4u3n1n

The management of carbapenem-resistant infections is often based on polymyxins, tigecycline, aminoglycosides and their combinations. However, in a recent systematic review, we found that Gram-negative bacteria (GNB) co-resistant to carbapanems, aminoglycosides, polymyxins and tigecycline (CAPT-resistant) are increasingly being reported worldwide. Clinical data to guide the treatment of CAPT-resistant GNB are scarce and based exclusively on few case reports and small case series, but seem to indicate that appropriate (in vitro active) antimicrobial regimens, including newer antibiotics and synergistic combinations, may be associated with lower mortality. In this review, we consolidate the available literature to inform clinicians dealing with CAPT-resistant GNB about treatment options by considering the mechanisms of resistance to carbapenems. In combination with rapid diagnostic methods that allow fast detection of carbapenemase production, the approach proposed in this review may guide a timely and targeted treatment of patients with infections by CAPT-resistant GNB. Specifically, we focus on the three most problematic species, namely Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Several treatment options are currently available for CAPT-resistant K. pneumonia. Newer β-lactam-β-lactamase combinations, including the combination of ceftazidime/avibactam with aztreonam against metallo-β-lactamase-producing isolates, appear to be more effective compared to combinations of older agents. Options for P. aeruginosa (especially metallo-β-lactamase-producing strains) and A. baumannii remain limited. Synergistic combination of older agents (e.g., polymyxin- or fosfomycin-based synergistic combinations) may represent a last resort option, but their use against CAPT-resistant GNB requires further study.

For the management of carbapenem-resistant Gram-negative bacteria (GNB), clinicians often resort to combination therapy based on polymyxins (including colistin or polymyxin B), aminoglycosides and tigecycline [1, 2] . However, in a recent systematic review of the literature, we found that GNB with simultaneous resistance to carbapenems, aminoglycosides, polymyxins and tigecycline (CAPT-resistant), are increasingly being reported worldwide [3] . The CAPTresistance phenotype is predominantly encountered in Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. It typically affects severely ill patients and patients in intensive care units, but the potential for hospital-wide dissemination or between health-care facilities has been well documented [3] .

All-cause mortality of patients with infections by CAPTresistant GNB is high (ranging from 20 to 71%) [3] . The limited available clinical evidence, based on case reports and small case series, seems to indicate that appropriate treatment (based on in vitro susceptibility) with newer antibiotics or synergistic combinations may reduce mortality [3] . However, guidance about treatment options for CAPT-resistant bacteria is lacking.

This review aims to consolidate the available literature to inform clinicians dealing with CAPT-resistant GNB about the available treatment options by considering the mechanisms of carbapenem resistance of the three most problematic GNB species, namely K. pneumoniae, A. baumannii and P. aeruginosa [3] [4] [5] .

The mechanisms of resistance to carbapenems (predominantly carbapenemase production, as discussed later) are independent of the mechanisms of resistance to last resort antibiotics such as polymyxins (resistance predominantly mediated by plasmid-or chromosomally mediated modification of the lipopolysaccharide [6] [7] [8] [9] ), aminoglycosides (predominantly mediated by aminoglycoside modifying enzymes or 16S ribosomal RNA methyltransferases [10] ), and tigecycline (predominantly mediated by overexpression of efflux pumps [8, 11, 12] ). Therefore, newer β-lactam/βlactamase inhibitor antibiotics and combinations that can overcome resistance mediated by carbapenemase production are still useful for CAPT-resistant GNB.

The usefulness of an approach based on the mechanism of resistance becomes clearer when laboratory methods to rapidly determine the mechanism of resistance are available to the clinician [13] [14] [15] [16] . Delays in determining antimicrobial susceptibility with traditional growth-based laboratory methods, such as broth microdilution, disk diffusion, gradient tests and agar dilution, may result in inappropriate empirical therapy, which may be associated with prolonged hospital stay and increased mortality [3, [17] [18] [19] . Rapid diagnostic methods, such as nucleic acid-based tests that detect carbapenemase genes, phenotypic assays that detect hydrolysis of carbapenems including MALDI-TOF mass spectrometry, and immunochromatographic assays, allow faster detection of carbapenemase production and many methods can even determine the most prevalent types of carbapenemases (e.g., KPC, VIM, NDM, OXA-48-like) [15, 16, [20] [21] [22] [23] . Many of these methods can be implemented directly on spiked blood cultures [23, 24], allowing even earlier identification of the mechanisms of resistance and targeted treatment in a timely manner.

However, considering the limitations of some rapid diagnostic methods regarding the detection of rare or novel β-lactamase variants [23, [25] [26] [27] , susceptibility to the selected treatment regimen should always be confirmed with traditional growth-based methods. Pending such confirmation (and taking into consideration local epidemiological data), it may be reasonable to use combination empirical therapy for severely ill patients at risk for carbapenem-resistant infections [17] .

Understanding the molecular mechanisms of resistance to carbapenems is the most useful first step to guide the treatment of CAPT-resistant GNB. Several mechanisms can result in resistance to carbapenems [28]: (1) production of carbapenemases, (2) mutation of porins resulting in reduced outer membrane permeability, (3) overexpression of efflux pumps, (4) target modification (rare). A combination of these mechanisms is also possible. The mechanisms used by each of the three species reviewed here vary significantly in prevalence, not only between different species but also between different countries or regions [10, [29] [30] [31] [32] [33] ].

Production of carbapenemases, which are typically acquired by horizontal gene transfer, is the predominant mechanism responsible for carbapenem resistance in K. pneumoniae [10, 34] . The type of carbapenemase is highly variable in different geographical regions [10, 29, 30] . Metallo-beta lactamases (MBL) appear to be substantially more prevalent in Asia (especially the Indian subcontinent) and in some European countries [29, 30] , with an increasing prevalence following the introduction of ceftazidime/avibactam [35] . In contrast, OXA-48-like carbapenemases are most prevalent in countries of the Mediterranean Basin, especially Turkey [10, 29] . In the USA, Canada, Latin America, China and some European countries (mainly Italy and Greece), KPCs are the most prevalent carbapenemases [10, 29, 36] . The frequency of carbapenemase-negative carbapenem-resistant K. pneumoniae is also highly variable in different countries and continents [10, 30, 34] . Porin mutations or efflux pump overexpression (often combined with the production of betalactamases) appear to be responsible for the resistance in carbapenemase-negative K. pneumoniae [37] [38] [39] [40] . [63] [64] [65] [66] [67] . These mutations may reverse the susceptibility to carbapenems [65, 67, 68] , but switching to carbapenem monotherapy in such cases may re-select for carbapenem resistance [69] . Meropenem/ vaborbactam [70] and imipenem/relebactam [62] remain active against some KPC variants conferring resistance to ceftazidime/avibactam, and against the recently described VEB-25 extended spectrum β-lactamase that has been associated with ceftazidime/avibactam resistance [26] . Furthermore, emergence of resistance may be less likely compared to ceftazidime/avibactam [66, 71] . Finally, several case reports and small series have reported successful treatment of CAPT-resistant KPC-producing K. pneumoniae with a double carbapenem combination [72] [73] [74] [75] . The rationale of this combination is that ertapenem due to its higher affinity with the carbapenemase enzyme acts as a suicide inhibitor, allowing higher levels of the second carbapenem (typically meropenem or doripenem) [72] [73] [74] [75] .

On the other hand, options for MBL-producing K. pneumoniae are limited. The novel β-lactam-β-lactamase inhibitor combinations, including ceftazidime/avibactam [59], ceftolozane/tazobactam [76] , meropenem/vaborbactam [77] and imipenem/relebactam [55] , are inactive against MBL-producing GNB [78] . In contrast, the combination of aztreonam with avibactam may restore activity against MBL-producing isolates [60, 79] , because aztreonam is not hydrolyzed by MBLs and avibactam effectively inhibits other beta-lactamases (ESBL, KPC and OXA-48) that can hydrolyze aztreonam. The combination aztreonam-avibactam is not currently available, but the combination of ceftazidime-avibactam plus aztreonam has been used successfully against infections by MBLproducing bacteria [80] [81] [82] [83] .

Plazomicin is more active compared to alternative aminoglycosides against carbapenem-resistant Enterobacterales regardless of the mechanism of carbapenem resistance [10] , and is active against polymyxin-resistant Enterobacterales, regardless of the mechanism of polymyxin resistance [84] . However, production of 16S-rRNA-methyltransferases (which confer resistance to plazomicin) is encountered in up to 60% of MBL-producing K. pneumoniae [10] .

Several options are also available for carbapenemase-negative carbapenem-resistant K. pneumoniae. Plazomicin is active against the majority (95%) of carbapenemase-negative carbapenem-resistant Enterobacterales [10] . Isolates with outer membrane permeability changes (typically OmpK35 and OmpK36 porin mutations) often remain susceptible to ceftazidime/avibactam [85] [86] [87] , meropenem/vaborbactam [88] and imipenem/relebactam [62, 89] , albeit with higher MICs. A theoretical concern in such cases is that with an MIC closer to the susceptibility breakpoint, emergence of resistance may be more likely by stepwise accumulation of multiple chromosomally mediated resistance mechanisms, including mutations resulting in reduced membrane permeability, overexpression of efflux pumps, overexpression of β-lactamases or mutations attenuating the effect of β-lactamase inhibitors [87, 90] .

Other potential options for CAPT-resistant K. pneumoniae include eravacycline, fosfomycin and cefiderocol. Eravacycline is more potent compared to tigecycline and may be active against some tigecycline-resistant strains (especially considering the current EUCAST susceptibility breakpoint for tigecycline) [91, 92] . Successful use of fosfomycin against extensively drug-resistant K. pneumoniae has been reported in small case series, often in combination with other antimicrobials [93, 94] . Despite concerns about development of resistance during treatment, this does not appear to be a problem in clinical practice possibly because fosfomycin resistance may carry a biological fitness cost [95, 96] .

Finally, synergistic combinations, such as colistin-based combinations [97, 98] or combination of fosfomycin with carbapenems [94, 99] , may prove useful last-resort options, but pharmacodynamic/pharmacokinetic (PK/PD) and clinical studies are lacking, especially against isolates co-resistant to all components of the combinations [3] . Synergistic combinations based on ceftazidime/avibactam (combined with fosfomycin + aztreonam or meropenem) have also been reported for the treatment of ceftazidime/avibactam-resistant strains [26] . Combinations exploiting multiple heteroresistance is another interesting option and may be effective against pan-resistant K. pneumoniae based on in vitro and in vivo animal data [100] .

Based on the above evidence synthesis, treatment options for CAPT-resistant K. pneumoniae are summarized in Fig. 1 .

In contrast to CAPT-resistant K. pneumoniae, meropenem-vaborbactam and plazomicin are not useful for CAPTresistant P. aeruginosa. The activity of meropenem-vaborbactam is similar to that of meropenem alone [61] and plazomicin is not better than older aminoglycosides against P. aeruginosa [10] .

On the other hand, ceftazidime/avibactam and ceftolozane/tazobactam may retain activity against selected CAPTresistant P. aeruginosa strains. Both are less prone to outer membrane permeability changes (porin loss/efflux pumps) and neither is affected by AmpC (ceftolozane is stable against AmpC and avibactam restores the activity of ceftazidime by inhibition of AmpC) [101, 102] . Therefore, both ceftazidime/avibactam and ceftolozane/tazobactam remain highly active (81-92% [101, [103] [104] [105] [106] ) against non-MBL carbapenem-resistant P. aeruginosa, but susceptibility may be much lower (41-48% [45, 103] ) in isolates co-resistant to multiple anti-pseudomonal beta-lactams (ceftazidime, piperacillin/tazobactam and cefepime). Generally, ceftolozane/ tazobactam appears to be more potent than ceftazidime/ avibactam in non-carbapenemase-producing P. aeruginosa [101, 102] , and has been used successfully against ventilator-associated pneumonia by CAPT-resistant P. aeruginosa [107] .

Resistance to ceftazidime/avibactam and ceftolozane/ tazobactam is usually the result of structural modifications of AmpC (in addition to overexpression) or horizontally acquired carbapenemases [108, 109] . Imipenem-relebactam, another option against non-MBL producing P. aeruginosa [110] , is not affected by AmpC mutations that confer resistance to ceftazidime/avibactam and ceftolozane/tazobactam [110] . However, GES-producing P. aeruginosa strains are resistant to both imipenem/relebactam [46, 47] and ceftolozane/tazobactam [45, 111] , but may be susceptible against ceftazidime/avibactam [45, 111] .

Neither imipenem/relebactam nor ceftolozane/tazobactam or ceftazidime/avibactam is active against MBL-producing P. aeruginosa [55, 59, 76] . Furthermore, in contrast to MBL-producing K. pneumoniae, aztreonam/avibactam cannot overcome resistance against most MBL-producing P. aeruginosa due to mechanisms of resistance to aztreonam independent of beta-lactamases [112] . Nevertheless, the combination of ceftazidime/avibactam with aztreonam may be useful against selected strains, with intermediate/ borderline MICs to aztreonam or ceftazidime/avibactam [81, 113] . Cefiderocol on the other hand is stable to hydrolysis by all carbapenemases (including MBL and OXA) and is not affected by porin/efflux pumps mutations [114] [115] [116] . It is therefore a useful option when everything else is ineffective.

Fosfomycin has also been used successfully against CAPT-resistant P. aeruginosa [93] . However, fosfomycin monotherapy should be avoided in P. aeruginosa infections given the risk of emergence of resistance during treatment [117] [118] [119] . Finally, various synergistic combinations (e.g., based on colistin [120, 121] , fosfomycin [122, 123] or aminoglycosides [45]) may represent a last resort treatment option. The combination of ceftolozane-tazobactam with amikacin [45] or fosfomycin [122] may also be effective based on in vitro evidence.

Based on this evidence synthesis, treatment options for CAPT-resistant P. aeruginosa are summarized in Fig. 2 .

Options for CAPT-resistant A. baumannii are limited. This is reasonable considering the multiple concurrent mechanisms of resistance in A. baumannii, including reduced membrane permeability, increased efflux and Class B and D carbapenemase production. None of the new β-lactam-βlactamase inhibitor combinations (meropenem/vaborbactam, imipenem/relebactam, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam/avibactam) are active against carbapenem-resistant A. baumannii [61, [124] [125] [126] [127] . Furthermore, plazomicin does not have better activity compared to alternative aminoglycosides [10] , and A. baumannii appears to be intrinsically resistant to fosfomycin [96, 128] .

Potential currently available options for CAPT-resistant A. baumannii include minocycline, eravacycline and cefiderocol. Eravacycline is more potent compared to tigecycline and may be an option against some tigecyclineresistant A. baumannii strains [92, [129] [130] [131] . Minocycline has also been proposed as an option and has been used against carbapenem-resistant isolates [132] , but its role and activity against CAPT-resistant isolates is unclear, especially considering that its susceptibility breakpoints are unclear [133] and the lack of modern PK/PD studies and randomized controlled trials [134] . Finally, cefiderocol is active against most A. baumannii, but cefiderocolresistant strains have already been reported [114, 135] [72] [73] [74] [75] . 5 Plazomicin is active against 93% of KPC-producing, 42% of MBLproducing (co-production of 16S-rRNA-methyltransferases), 87% of OXA-producing, and 95% of carbapenemase-negative carbapenemresistant Enterobacterales [10] . 6 Fosfomycin has been shown to be effective against XDR/PDR K. pneumoniae [93, 94] , but its activity is highly variable [96] . 7 Cefiderocol is stable against hydrolysis by all carbapenemases (including MBL) and its mechanism of bacterial cell entry is independent of porin channels and efflux pumps. Therefore, cefiderocol appears to be a useful option when no other antibiotic is active [114, 115] . 8 Eravacycline is more potent compared to tigecycline and may be active against some tigecycline-resistant strains [91, 92] . 9 Options include combinations based on colistin [97, 98] , fosfomycin [94, 99] [110] . Moreover, IMI/REL is not affected by AmpC mutations that confer resistance to ceftazidime/avibactam and ceftolozane/tazobactam [110] . IMI/REL is ineffective against MBL-and GES-producing P. aeruginosa strains [46, 47]. 4 Cefiderocol is stable against hydrolysis by all carbapenemases (including MBL) and its mechanism of bacterial cell entry is independent from porin channels and efflux pumps. Therefore, cefiderocol appears to be a useful option when no other antibiotic is active [114, 115] . 5 Alternative antibiotics (if available) may be preferable taking into account the concerns for emergence of resistance during treatment with fosfomycin [96, 117] . When fosfomycin is used it should be combined with a second antibiotic. 6 High-dose aminoglycoside therapy (such as amikacin 50 mg/kg/day) may be a useful option for CACT-resistant P. aeruginosa with borderline MIC (e.g., amikacin MIC = 16 mg/dl) and can be combined with hemodialysis to reduce nephrotoxicity [184, 186, 187] . 7 Until cefiderocol becomes widely available, synergistic combinations (e.g., based on colistin [120, 121] , fosfomycin [122, 123] .: Plazomicin is no better than other aminoglycosides against P. aeruginosa [10] .: Similar to other tetracyclines, P. aeruginosa is resistant to eravacycline [91] .: Aztreonam/avibactam cannot overcome resistance against most MBL-producing P. aeruginosa [112] , but may be useful against selected strains with borderline/intermediate MICs to aztreonam or ceftazidime/avibactam [81, 113] predominantly against carbapenem-resistant polymyxin-susceptible A. baumannii, and clinical benefit has not yet been found in most studies [2, [139] [140] [141] [142] [143] [144] . Differences between in vitro and in vivo conditions, such as insufficient drug concentrations, insufficient exposure time to synergistic concentrations, host immune-pathogen interactions and fitness cost associated with polymyxin resistance have been proposed as potential explanations [140, 141, 145] . Furthermore, most studies on polymyxin-based combinations have been conducted with colistin [146] . However, polymyxin B has important pharmacokinetic advantages and is less nephrotoxic [147] [148] [149] , and according to a recent international consensus should be preferred over colistin except for lower urinary tract infections [146] . Therefore, clinical data are needed to assess the impact of polymyxin B-based combination regimens [146] . Despite the above limitations, polymyxin-based combinations may be useful for the management of CAPT-resistant A. baumannii based on in vitro and animal studies [120, 144, [150] [151] [152] and limited clinical data [153] [154] [155] [156] [157] [158] . For example, the combination of colistin with rifampicin has been used successfully against colistin-resistant A. baumannii pneumonia [154] and colistin-resistant A. baumannii postsurgical meningitis [156, 157] . Notable is the synergy between colistin and agents that are not active against Gram-negative bacteria (such as linezolid and vancomycin), suggesting that colistin may exert a sub-inhibitory permeabilizing effect that allows increased entry of other drugs into the bacteria [150, 159] .

High-dose ampicillin-sulbactam combined with meropenem and polymyxins is another promising combination [153, 160, 161] , and has been used successfully against CAPTresistant A. baumannii ventilator-associated pneumonia [153] . Furthermore, based on a recent in vitro study, the combination sulbactam/avibactam (which can be currently achieved by combining ampicillin/sulbactam with ceftazidime/avibactam) may be useful against non-MBL-producing A. baumannii [162] . The rationale of this combination is that avibactam can inhibit most of the beta-lactamases that can affect the activity of sulbactam [162] .

Tigecycline-based combinations have also been proposed, but have predominantly been studied against tigecyclinesusceptible strains, or in combination with an in vitro active agent (predominantly colistin) [163] . Although data regarding tigecycline-based combinations against CAPT-resistant GNB are limited, such combinations are often used in clinical practice given the lack of other options [158, 164] . Synergistic combinations with minocycline may also prove useful [144] , but currently available data are very limited.

In summary, older agents (including minocycline, ampicillin/sulbactam and trimethoprim/sulfamethoxazole) may be an option against CAPT-resistant A. baumannii if in vitro active and have been used mainly in combination with other agents. Among newer (currently approved) agents, eravacycline and cefiderocol are other options. If none of the above options are active, or where newer agents are not yet available, polymyxin-, tigecycline-and sulbactam-based synergistic combinations may prove useful, but their role against CAPT-resistant strains remains understudied.

Randomized controlled trials providing robust evidence to guide the selection of one agent over the other are lacking [3, 66, 165] . Approval of newer antimicrobials is usually based on non-inferiority trial designs, which have several limitations including insufficient power to assess the superiority of one antimicrobial over the other and even the possibility of bias favoring non-inferiority [165] . Furthermore, trials of new antimicrobials are often conducted in patients with carbapenem-susceptible infections and their results are extrapolated to patients with more resistant infections based on in vitro susceptibility data [14, 165] . Post-marketing adaptive randomized controlled trial designs have been proposed to assess newer antimicrobials for patients with multidrugresistant GNB infections, who were not included in earlier phase studies [165] . Use of rapid diagnostic methods, combined with utilization of algorithms guided by mechanisms of resistance (such as those proposed here), may guide a more efficient targeting of newer antimicrobials in clinical trials [14, 165] .

The available evidence, predominantly based on real rife observational data, suggests the superiority of beta-lactambased therapy (i.e., double-carbapenem [166] or newer β-lactam-β-lactamase combination regimens such as ceftazidime/avibactam [66, [167] [168] [169] [170] , meropenem/vaborbactam [66, 171] or imipenem/relebactam [172] ) over older antimicrobial options (including polymyxins, aminoglycosides, tigecycline and their combinations) against carbapenemresistant Enterobacterales. Furthermore, in a recent multicenter observational study, the combination of ceftazidime/ avibactam with aztreonam was associated with significantly lower clinical failure, mortality and length of stay compared to other active agents (including combinations of polymyxins, tigecycline, aminoglycosides and fosfomycin) for bloodstream infection by MBL-producing Enterobacterales (predominantly K. pneumoniae) [83] . Moreover, ceftazidime/ avibactam has been used successfully as salvage therapy against infections by carbapenem-resistant K. pneumoniae that have failed various combination regimens [173] . Ceftazidime/avibactam and meropenem/vaborbactam appear to have similar efficacy, although emergence of resistance during treatment is more common with ceftazidime/avibactam monotherapy [71] . Nevertheless, based on limited available data, ceftazidime/avibactam monotherapy and combination therapy are associated with similar outcomes [170, 174] .

Clinical data for other options (including fosfomycin, eravacycline, minocycline, plazomicin, cefiderocol, synergistic combinations) against carbapenem-resistant bacteria are still limited. The results of the prematurely terminated CARE trial seem to favor plazomicin over colistin-based combinations, although the number of patients enrolled was very small [175] . Eravacycline appears to be a good option extrapolating from trials of carbepenem-susceptible infections [177] , but data against carbapenem-resistant infections are limited [176] . Minocycline has shown favorable efficacy against carbapenem-resistant A. baumannii [132, 178] , but the activity of minocycline against tigecycline-resistant strains is unclear considering the lack of modern PK/PD studies and unclear susceptibility breakpoints [133, 134] . Intravenous fosfomycin has been used successfully against extensively drug-resistant and CAPT-resistant GNB in small case series [93, 94] . Cefiderocol has been used successfully as a last resort option, but the limited available data against carbapenem-resistant bacteria are conflicting [179] . Finally, several in vitro studies have evaluated synergistic combinations, but clinical data against isolates co-resistant to all components of the combinations are limited to small series or case reports [3, 153, 154, [156] [157] [158] .

With the currently recommended treatment regimen for ceftazidime/avibactam (2 + 0.5 g every 8 h by 2 h intravenous infusion, adjusted for renal function) a high probability (> 90%) of target attainment against MIC ≤ 8 mg/l can be achieved regardless of older age, obesity, augmented renal clearance, or severity of infection [180, 181] . Prolonged or continuous infusion of ceftazidime/avibactam does not seem to improve PD target attainment compared to the standard 2 h infusion [182] . However, the optimal regimen for the combination of ceftazidime/avibactam with aztreonam for MBL-producing Enterobacterales remains unclear [13, 83] . In the largest cohort, the regimen used was: ceftazidime/ avibactam 2 + 0.5 g every 8 h (administered as a prolonged 8 h infusion in half of the patients and as a 2 h infusion in the rest) and aztreonam 2 g every 8 h (administered as a 2 h infusion) [83] . Based on a recent study using a hollow-fiber infection model comparing the effect of various regimens on bacterial killing and suppression of resistance, the following were proposed [183] : (1) simultaneous administration of ceftazidime/avibactam with aztreonam is preferred to staggered administration (ceftazidime/avibactam first, followed by aztreonam), (2) continuous infusion and standard 2 h infusion appear to be equally effective, (3) a total daily dose of 8 g aztreonam may be superior to 6 g. However, only two NDM-1-producing E. coli and K. pneumoniae strains were used in the study and validation of these results in more strains is necessary [183] .

Reviewing the dosing regimens and PK/PD considerations for each of the antimicrobials discussed in this manuscript is beyond the scope of this review. However, it is worth highlighting the potential of attaining PD targets in selected cases when the MIC is above the susceptibility breakpoint with higher dose (for concentration-dependent antimicrobials) or prolonged/continuous infusion regimens (for timedependent antimicrobials). For example, two patients with renal failure and sepsis by pandrug-resistant P. aeruginosa were successfully treated with high-dose amikacin monotherapy (25 and 50 mg/kg/day, respectively) despite an MIC of 16 mg/L [184] . Continuous venovenous hemodiafiltration was used to enhance extrarenal clearance of amikacin and achieve low trough concentrations to reduce the risk of otherwise unavoidable nephrotoxicity [185] . In both patients, the peak amikacin concentration was eight to ten times the MIC and renal function was preserved [184] . Combining high-dose aminoglycosides (to achieve PD targets) with hemodialysis (to increase clearance and decrease nephrotoxicity) is an interesting option [186, 187] , especially when no alternatives are available, but requires further study.

Based on PK/PD modeling with Monte Carlo simulations, optimized prolonged infusion treatment regimens to overcome resistance have been proposed for a variety of timedependent antimicrobials whose efficacy is best predicted by the time that the antibiotic's concentration is above the MIC (% T > MIC, or % f T > MIC considering the free, unbound drug concentration). For example, two-step administration of meropenem (1.5 g administered intravenously over 5 min followed by a 6 h infusion of 0.5 g, repeated every 8 h) can achieve a > 90% probability of target attainment for carbapenem-resistant isolates with MIC up to 128 mg/L (considering a target 50% f T > MIC), or up to 32 mg/L (considering a higher target of 50% f T > 5 × MIC) [188] . Regarding ceftolozane/tazobactam, an extended (4-5 h) infusion may perform better compared to shorter or longer infusions, especially in patients with augmented renal clearance, and has been proposed to achieve target attainment (40% fT > MIC) for P. aeruginosa strains with MIC up to 32 mg/dl [189] . Furthermore, prolonged or continuous infusion of sulbactam may allow target attainment (60% T > MIC) against A. baumannii strains with sulbactam MIC up to 32 mg/L [190, 191] . Finally, administration of fosfomycin as prolonged infusion (6 h infusions of 8 g every 8 h) may allow target attainment (70% T > MIC in this study) for P. aeruginosa with MIC up to 128 mg/L, while continuous infusion of 16 g/day may allow target attainment for strains with MIC up to 96 mg/L [192] . However, fosfomycin-resistant subpopulations rapidly emerge, especially from strains with higher baseline MIC and fosfomycin heteroresistance [118, 119, 193, 194] . Therefore, the benefits of prolonged or continuous fosfomycin infusion may be more apparent when used in synergistic combination regimens [118, 192] , especially when the second antibiotic can counterselect resistance amplification by exploiting multiple heteroresistance [100] . Clinical data for the use the above options are not available.

Direct delivery at the site of infection may also be an option to achieve sufficient antibiotic concentration and attain PD targets. For example, a case of meningitis by pandrug-resistant P. aeruginosa (with amikacin MIC 32 mg/L) was successfully treated with intraventricular amikacin [195] . PK/PD considerations for intrathecal administration of antibiotics are discussed in detail in a recent review [196] . Intravesical administration of antibiotics (e.g., colistin or aminoglycosides [197, 198] ) may also be an option for lower urinary tract infections, but clinical data against CAPT-resistant GNB are lacking.

Understanding the molecular mechanisms of resistance and the local epidemiology of these mechanisms is crucial in guiding decision-making when selecting appropriate (in vitro active) antimicrobials for the management of CAPT-resistant GNB. This understanding becomes particularly useful in the presence of laboratory methods that can rapidly determine the molecular mechanisms of resistance. Several such methods are available, including lower-cost phenotypical assays, and are suitable for microbiology laboratories of any capacity. This review shows that several treatment options are available against CAPTresistant K. pneumoniae and against non-MBL CAPTresistant P. aeruginosa, but controlled trials to guide the selection of one agent over the other are still lacking. On the contrary, options for MBL-producing P. aeruginosa and CAPT-resistant A. baumannii are limited. Cefiderocol and other novel agents under development are promising future options. Until new agents become widely available in clinical practice, more research (including PK/PD and outcome studies) on the effectiveness of synergistic combinations or optimized prolonged infusion regimens might help.

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment

Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options

Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Molecular mechanisms related to colistin resistance in Enterobacteriaceae

Colistin and its role in the era of antibiotic resistance: an extended review

A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii

Colistin heteroresistance in Acinetobacter spp; systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications

Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms

Minocycline and tigecycline: what is their role in the treatment of carbapenem-resistant Gram-negative organisms? Microb Drug Resist

Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance

Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the omega-loop

In vitro selection of Ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase

Emergence of Ceftazidime-avibactam resistance due to plasmid-borne blakpc-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections

Ceftazidime/avibactam, meropenem/vaborbactam, or both? clinical and formulary considerations

Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to Ceftazidime-avibactam and exhibiting reduced carbapenemase activity

Mutations in blaKPC-3 that confer Ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases

In vitro selection of meropenem resistance among Ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases

Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenemresistant Enterobacteriaceae

Meropenem-vaborbactam versus Ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections

Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae

Combination antibiotic therapy in pan-resistant klebsiella pneumoniae infection: a report of two cases

Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen

Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in intensive care units in Spain: the SUPERIOR multicentre study

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

Novel betalactam-beta-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens

In Vitro Activity of Ceftazidime-avibactam and aztreonamavibactam against OXA-48-carrying enterobacteriaceae isolated as part of the international network for optimal resistance monitoring (INFORM) global surveillance program from 2012 to 2015

Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection

Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by Metallo-beta-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa

Aztreonam plus clavulanate, tazobactam or avibactam for the treatment of metallo-beta-lactamase-producing-Gram negative related infections

Efficacy of Ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales

Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates

Role of the outer membrane and porins in susceptibility of beta-lactamase-producing Enterobacteriaceae to Ceftazidime-avibactam

Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of Ceftazidime-avibactam against carbapenem-resistant K pneumoniae

Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values

610 Meropenem-vaborbactam (MV) In vitro activity against carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates with outer membrane porin gene mutations. Open Forum Infect Dis

Activity of Imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant

Resistance to ceftazidime/avibactam plus meropenem/vaborbactam when both are used together achieved in four steps from metalloβ-lactamase negative Klebsiella pneumoniae

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015

In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemaseproducing Gram-negative bacteria

Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem

Fosfomycin for Injection (ZTI-01) Versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial

Resistance to fosfomycin: mechanisms, frequency and clinical consequences

Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae

Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics

In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/ or NDM-producing Klebsiella pneumoniae

Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection

Evaluation of the in vitro activity of Ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates

Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms

In vitro activity of ceftolozane-tazobactam and Ceftazidime-avibactam against clinical isolates of meropenem-nonsusceptible Pseudomonas aeruginosa: a two-center study

Multicenter evaluation of Ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds

Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates

Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new beta-lactam combination agents

Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa

Mechanisms leading to in vivo ceftolozane/ tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC

Activity of imipenem/ relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic beta-lactam resistant mutants

Acquisition of extended-spectrum β-lactamase ges-6 leading to resistance to ceftolozane-tazobactam combination in Pseudomonas aeruginosa

In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015

Evaluation of the synergy of Ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrugresistant Klebsiella pneumoniae and Pseudomonas aeruginosa

In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria

Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa

Determination of the dynamically linked indices of fosfomycin for Pseudomonas aeruginosa in the hollow fiber infection model

Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model

In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates

Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa

Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa

In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

The β-lactams strike back: Ceftazidime-avibactam

In Vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates

Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii

In-vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii

In-vitro activity of the novel fluorocycline eravacycline against carbapenem nonsusceptible Acinetobacter baumannii

In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates

The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence

Minocycline susceptibility breakpoints for Acinetobacter baumannii: do we need to re-evaluate them?

Revival of old antibiotics: needs, the state of evidence and expectations

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)

Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study

Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis

Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies

Colistin plus meropenem for carbapenemresistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Polymyxins: to combine or not to combine?

Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter

Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenemresistant Acinetobacter baumannii infections

Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxinresistant strain of Acinetobacter baumannii

Re: 'colistin plus meropenem for carbapenem-resistant Gram-negative infections in vitro synergism is not associated with better clinical outcomes' by Nutman

European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), Society of critical care medicine (SCCM), and Society of infectious diseases pharmacists (SIDP). Pharmacotherapy

Colistin and polymyxin B: peas in a pod, or chalk and cheese?

Polymyxin B versus colistin: an update

Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother

In Vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity

Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin

Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study

Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial

In vitro activity of colistin mono-and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital

Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii

Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin

Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drugresistant Gram-negative bacteria

Antimicrobial combinations against panresistant Acinetobacter baumannii isolates with different resistance mechanisms

High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model

Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance

In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii

Vitro activity of various antibiotics in combination with tigecycline against Acinetobacter baumannii: a systematic review and meta-analysis

Extensive drug resistant Acinetobacter baumannii: a comparative study between non-colistin based combinations

Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials

Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis

Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae Bacteremia

Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPCproducing Klebsiella pneumoniae

Colistin versus Ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae

Ceftazidime-avibactam combination therapy compared to Ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis

Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis

Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 Phase 3 trial of imipenemcilastatin-relebactam versus colistin plus imipenem-cilastatin in patients with imipenem-nonsusceptible bacterial infections

Efficacy of Ceftazidime-avibactam salvage therapy in patients with infections Caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae

Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a metaanalysis

Plazomicin for infections caused by carbapenemresistant Enterobacteriaceae

Early experience with eravacycline for complicated infections

Evaluation of eravacycline: a novel fluorocycline

Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

Case commentary: the need for Cefiderocol is clear, but are the supporting clinical data? Antimicrob Agents Chemother

Dose selection and validation for Ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and Nosocomial Pneumonia

Selecting the dosage of Ceftazidime-avibactam in the perfect storm of nosocomial pneumonia

Pharmacokinetic-Pharmacodynamic target attainment analyses to determine optimal dosing of Ceftazidime-avibactam for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model

Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

Back to the future: using aminoglycosides again and how to dose them optimally

Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model

A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study

Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? a pharmacokinetic/pharmacodynamic modeling with monte carlo simulation

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L

Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii

Population pharmacokinetics and monte carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii

Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation

Oral Fosfomycin efficacy with variable urinary exposures following single and multiple doses against Enterobacterales: the importance of heteroresistance for growth outcome

Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis

Intrathecal antibacterial and antifungal therapies

Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature

Use and effectiveness of antimicrobial intravesical treatment for Prophylaxis and treatment of recurrent urinary tract infections (UTIs): a systematic review